Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749190 · ClinicalTrials.gov registry record · Phase 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 495
- Enrollment target
NCT00749190 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 495 participants.
The verdict
NCT00749190, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 495 participants
- Enrollment target
Study Summary
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM with insufficient glycemic control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM) as add-on therapy to metformin.
Interventions
- DRUG placebo
- DRUG sitagliptin
- DRUG BI 10773
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749190
The ClinicalTrials.gov registry entry for NCT00749190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00749190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749190 about?
NCT00749190 is a clinical study titled "BI 10773 add-on to Metformin in Patients With Type 2 Diabetes". The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM with insufficient glycemic control. In addition, there will be an open...
What is the current status of trial NCT00749190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 495 participants. The study started on 2008-08.
What interventions are being tested in trial NCT00749190?
The interventions under investigation include: placebo (DRUG), sitagliptin (DRUG), BI 10773 (DRUG).
Who is sponsoring clinical trial NCT00749190?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.